Glen Harbor Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Glen Harbor Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-115	Closed	-$106K	–	1354
2019 Q2	$106K	Buy	115 +27	+31%	+$33.2K	﹤0.01%	1159
2019 Q1	$141K	Hold	88	–	–	﹤0.01%	1080
2018 Q4	$165K	Hold	88	–	–	﹤0.01%	1003
2018 Q3	$208K	Hold	88	–	–	﹤0.01%	1032
2018 Q2	$305K	Hold	88	–	–	0.01%	833
2018 Q1	$251K	Hold	88	–	–	0.01%	891
2017 Q4	$228K	Buy	88 +31	+54%	+$88.1K	0.01%	931
2017 Q3	$161K	Buy	57 +10	+21%	+$26.3K	﹤0.01%	986
2017 Q2	$110K	Buy	47 +22	+88%	+$43.6K	﹤0.01%	1064
2017 Q1	$62K	Buy	25 +2	+9%	+$5.76K	﹤0.01%	1083
2016 Q4	$52K	Buy	+23	New	+$54.7K	﹤0.01%	1084

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Harbor Capital Management's ACOR Position: Q3 2019 in Review

Glen Harbor Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 115 shares — an estimated $106K sold.

Glen Harbor Capital Management first reported a position in ACOR in Q4 2016 and held it in 11 quarters. The position peaked at $305K in Q2 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

Glen Harbor Capital Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
Glen Harbor Capital Management sold 115 Acorda Therapeutics shares in Q3 2019, an estimated $106K.
Glen Harbor Capital Management first reported a position in Acorda Therapeutics in Q4 2016 and held it in 11 quarters.
Glen Harbor Capital Management's Acorda Therapeutics position peaked at $305K in Q2 2018.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.